Latest Vanguard News

BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.

Talius Group has raised $4 million in a recent placement, expanding its subscription base and preparing to capitalize on new aged care legislation set to take effect in November 2025.

Vanguard Investments Australia has announced the estimated distribution and tax components for its Vanguard FTSE Asia ex Japan Shares Index ETF for the quarter ending September 2025, highlighting key details for investors on cash payouts and tax implications.

Vanguard Investments Australia has announced the Distribution Reinvestment Plan (DRP) issue prices for its suite of ETFs for the quarter ending 30 September 2025, outlining key dates and eligibility for investors.

Vanguard Investments Australia has announced estimated distribution amounts and a clear timetable for over 20 of its Australian-listed ETFs, with payments scheduled for mid-October 2025.

Vanguard Investments Australia has announced estimated distribution amounts for 20 of its ETFs, with payments scheduled for mid-October 2025. Investors can expect detailed income figures across Australian and international equity and fixed income funds.

Brightstar Resources has delivered a strong Definitive Feasibility Study for its Laverton and Menzies Gold Projects, targeting over 338,000 ounces of gold with promising financial returns, while ramping up underground mining operations and securing $50 million in capital.

BKI Investment Company posted a solid financial performance for FY2025 with a 1% increase in dividends and introduced a neutralised Dividend Reinvestment Plan to maintain capital neutrality. Despite modest portfolio underperformance against major ETFs, BKI continues to offer an attractive dividend yield amid shifting market dynamics.

Vanguard Investments Australia Limited will forgo half-yearly financial reports for select ETFs in their first short financial year, leveraging ASIC’s regulatory relief to streamline reporting.

Vanguard Investments Australia has announced estimated distribution amounts for a broad range of its ETFs, alongside key dates for July 2025. Investors can now anticipate income details and plan for upcoming payments across multiple funds.

Vanguard Investments Australia has announced estimated distribution amounts for over 30 ETFs, with payments scheduled for mid-July 2025. This detailed timetable offers investors clarity on income expectations and reinvestment options.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.